Two Hundred Gastrointestinal Stromal Tumors

DeMatteo, Ronald P.; Lewis, Jonathan J.; Leung, Denis H. Y.; Mudan, Salvinder S.; Woodruff, James M.; Brennan, Murray F.

doi:10.1097/00000658-200001000-00008

Cited by 2,185 publications

(687 citation statements)

References 25 publications

Supporting

Mentioning

648

Contrasting

Unclassified

Order By: Relevance

“…Three large retrospective studies from the Armed Forces Institute of Pathology (AFIP) added anatomical origin as an additional risk factor (Table 1). This addition was supported by DeMatteo et al (2000), who also added tumour size and mitotic rate (DeMatteo et al, 2000) as independent risk factors. The more recent phase III adjuvant imatinib trial, ACOSOG Z9001, also reported poorer long term outcomes in those patients with tumours arising from the small bowel (Corless et al, 2014).…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Gastrointestinal Stromal Tumours: A 10 Year Multicenter Audit

Watson¹,

Kelly²,

Malone³

et al. 2016

CCO

View full text Add to dashboard Cite

Background: Gastrointestinal stromal tumours (GISTs) are unique neoplasms of the gastrointestinal (GI) tract. The development of targeted therapeutic agents such as imatinib mesylate (Glivec) has altered the way on how we now manage these rare malignancies. The aim of this study was to evaluate the management of GISTs in three Irish tertiary hospitals. Methods: We performed a retrospective, multicenter audit of patients diagnosed with gastrointestinal stromal tumours over a ten year period (2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). Results: 110 patients were included in the study. Abdominal pain was the most common presenting symptom, reported in 30% of patients, while 31% were incidental findings. The stomach was the most common primary site of disease, observed in 77% of cases. 15 patients had metastatic disease at the time of diagnosis (14%), and 10 of these patients had liver involvement. More than half of patients (61%) were managed with surgical excision alone (61%), while 24 were managed with surveillance and 28 patients treated with adjuvant Glivec, which was generally well tolerated. 18 patients (20%) demonstrated recurrent or progressive disease after first line treatment. 102 patients (93%) are alive today. Conclusion: While surgery is widely regarded as the primary treatment modality for GISTs the addition of imatinib mesylate has enabled physicians to deliver more personalised treatment while optimising patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 78%

“…In cases where complete resection is not achieved, prognosis is poor, with median survival ranging from 10-23 months (DeMatteo et al, 2000). The addition of imatinib has revolutionised treatment in both the adjuvant and neoadjuvant setting, increasing median overall survival to 60 months (Otani et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Stromal Tumours: A 10 Year Multicenter Audit

Watson¹,

Kelly²,

Malone³

et al. 2016

CCO

View full text Add to dashboard Cite

show abstract

“…GISTs usually form between the muscle layer and the mucosa, growing into the intestinal space, the serosa, or possibly in both directions (2). They are most frequent in males, with an average age of 58 years old (3).…”

Section: Discussionmentioning

confidence: 99%

The endoscopic picture of upper digestive hemorrages secondary to stromal tumors (GIST): Report of two cases

Pérez

Paredes²,

Acosta

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

“…In a series of 200 GISTs, median survival was 66 months for complete resection compared with 22 months for incomplete resection or unresectable disease [18].…”

Section: Treatmentmentioning

confidence: 99%